The Innovative Medicines Initiative has now launched IMI2 – Call 13.
§ Assessment of the uniqueness of diabetic cardiomyopathy relative to other forms of heart failure using unbiased pheno-mapping approaches
§ Genome-environment interactions in inflammatory skin disease
§ The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use
§ Mitochondrial dysfunction in neurodegeneration
§ Support and coordination action for the projects in the neurodegeneration area of the Innovative Medicines Initiative
§ A sustainable European induced pluripotent stem cell platform
§ Linking digital assessment of mobility to clinical endpoints to support regulatory acceptance and clinical practice
§ Human tumour microenvironment immunoprofiling
§ ConcePTION – Continuum of evidence from pregnancy exposures, reproductive toxicology and breastfeeding to improve outcomes now
§ Improving the preclinical prediction of adverse effects of pharmaceuticals on the nervous system
§ Translational safety biomarker pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease
§ Pilot programme on a clinical compound bank for repurposing – this programme contains four topics on cardiovascular diseases and diabetes; respiratory diseases; neurodegenerative diseases; and rare/orphan diseases
Deadline for submitting short proposals: 28 February 2018
All topic texts, Call documentation and details of how to apply can be found on the IMI website – www.imi.europa.eu
Registration is open for the webinars on IMI2 – Call 13, which run until 15 December.
